Standard BioTools Inc. Advertising Expense
Standard BioTools Inc. (LAB) reported Advertising Expense of $2.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-03-16
- Standard BioTools Inc. advertising expense for fiscal 2025 was $2.20M, a 15.38% decline from fiscal 2024.
- Standard BioTools Inc. advertising expense for fiscal 2024 was $2.60M, a 30.00% increase from fiscal 2023.
- Standard BioTools Inc. advertising expense for fiscal 2023 was $2.00M, a 48.72% decline from fiscal 2022.
- Standard BioTools Inc. advertising expense for fiscal 2022 was $3.90M, a 14.71% increase from fiscal 2021.
| Period end | Advertising Expense 12 month | Advertising Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.20M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $2.60M 10-K · filed 2026-03-16 | $5.90M 10-K · filed 2025-03-11 |
| 2023-12-31 | $2.00M 10-K · filed 2026-03-16 | |
| 2022-12-31 | $3.90M 10-K · filed 2024-03-01 | |
| 2021-12-31 | $3.40M 10-K · filed 2023-03-14 | |
| 2020-12-31 | $1.60M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $3.40M 10-K · filed 2022-03-08 | |
| 2018-12-31 | $2.20M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $1.80M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $2.30M 10-K · filed 2019-03-18 | |
| 2015-12-31 | $2.90M 10-K · filed 2018-03-08 | |
| 2014-12-31 | $4.20M 10-K · filed 2017-03-03 | |
| 2013-12-31 | $2.40M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $1.30M 10-K · filed 2015-02-26 | |
| 2011-12-31 | $700.00K 10-K · filed 2014-03-12 | |
| 2010-12-31 | $500.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |